Management of infections during intensive treatment of hematologic malignancies

Annals of Hematology

Volumn 75, Issue 1-2, 1997, Pages 9-16

  Maschmeyer, G ^a   Hiddemann, W ^b   Link, H ^c   Cornely, O A ^d   Buchheidt, D ^e   Glass B ^f   Adam, D ^g  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF KIEL   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Fever; Infection; Leukemia; Neutropenia; Treatment

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; GLYCOPEPTIDE; HEMOPOIETIC GROWTH FACTOR; IMIPENEM; IMMUNOGLOBULIN; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

ACUTE LEUKEMIA; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; BLOOD DISEASE; CATHETER INFECTION; CLINICAL TRIAL; FEVER; GRAM NEGATIVE BACTERIUM; HUMAN; INFECTION CONTROL; LEUKEMIA REMISSION; LUNG INFILTRATE; MORTALITY; NEUTROPENIA; PATIENT CARE; PRIORITY JOURNAL; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; BACTERIAL INFECTIONS; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FEVER OF UNKNOWN ORIGIN; FORECASTING; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS, INTRAVENOUS; LACTAMS; LEUKOCYTE TRANSFUSION; MYCOSES; NEUTROPENIA; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; URINARY CATHETERIZATION; URINARY TRACT INFECTIONS;

EID: 0030815003     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050306     Document Type: Article

References (41)

1. Joshi JH, Schimpff SC, Tenney JH, Newman KA, De Jongh CA (1984) Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients? Am J Med 76:450-457
2. Link H, Maschmeyer G, Meyer P, Hiddemann W, Stille W, Helmerking M, Adam D (1994) Interventional antimicrobial therapy in febrile neutropenic patients. Ann Hematol 69:231-243
3. Valdivieso M (1976) Bacterial infection in haematological diseases. Clin Haematol 5:229-248
4. Maschmeyer G, Link H, Hiddemann W, Meyer P, Helmerking M, Eisenmann E, Schmitt J, Adam D (1994) Pulmonary infiltrations in febrile neutropenic patients. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer 73:2296-2304
5. Commers JR, Robichaud KJ, Pizzo PA (1984) New pulmonary infiltrates in granulocytopenic cancer patients being treated with antibiotics. Pediatr Infect Dis J 3:423-428
6. Bodey GP, Rodriguez V (1973) Advances in the management of Pseudomonas aeruginosa infections in cancer patients. Eur J Cancer 9:435-441
7. Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, Pizzo PA, Schimpff SC, Shenep JL, Wade JC, Young LS, Yow MD (1990) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161:381-396
8. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS (1992) Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 15 [Suppl 1]:206-215
9. Immunocompromised Host Society Consensus Panel (Pizzo PA, Armstrong D, Bodey G, De Pauw B, Feld R, Glauser M, Gaya H, Karp J, Klastersky J, Todeschini G, Verhoef J, Wade J, Young LS, Remington J) (1990) The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: report of a consensus panel for the Immunocompromised Host Society. J Infect Dis 161:397-401
10. Cometta A, Zinner S, De Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP, and the International Antimicrobial Therapy Cooperative Group of the European Organization for the Research and Treatment of cancer (1995) Piperacillin tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 39:445-452
11. Cometta A, Calandra T, Gaya H, Zinner SH, De Bock R, Del Favero A, Bucaneve G, Crokaert F, Kern WV, Klastersky J, Langenaeken J, Micozzi A, Padmos A, Paesmans M, Viscoli C, Glauser MP, and the International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program (1996) Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 40:1108-1115
12. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP, for the Intercontinental Antimicrobial Study Group (1994) Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. Ann Intern Med 120:834-844
13. Freifeld AG, Walsh T, Marshall D, Gress J, Steinberg SM, Hathorn J, Rubin M, Jarosinski P, Gill V, Young RC, Pizzo PA (1995) Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 13:165-176
14. Rolston KVI, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, Keating MJ, Holmes FA, Cabanillas FF, Elting L (1992) A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152:283-291
15. The Meropenem Study Group of Leuven, London and Nijmegen (1995) Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 36:185-200
16. Cornely OA, Hiddemann W, Link H, Maschmeyer G, Glass B, Buchheidt D, Wilhelm M, Büchner TH, Lipp TH, Haas R, Heinemann V, Helmerking M, and Adam D for the Study Group of the PEG (1997) Interventional antimicrobial therapy in febrile neutropenic patients - Paul Ehrlich Society for Chemotherapy (PEG) study II. Ann Hematol 74 [Suppl I]:A51
17. Walsh T, White M, Seibel N, Arnow P, Wiley J, Melcher G, Schiff D, Geyer R, Hiemenz J, Arndt C, van der Horst C, Myers B, Hilton E, Horowitz H, Levenstein M, Melamed S, Webb D, and the Early Empirical Antifungal Study Group (1996) Efficacy of early empirical fluconazole therapy in febrile neutropenic patients: results of a randomized, double-blind, placebo-controlled, multicenter trial. Proc Intersc Conf Antimicrob Agents Chemother 36:LB22
18. Donnelly JP (1991) Assessment and reporting of clinical trials of empirical therapy in neutropenic patients. J Antimicrob Chemother 27:377-387
19. Dompeling EC, Donnelly JP, Deresinski SC, Feld R, Lane-Allman EF, de Pauw BE (1996) Early identification of neutropenic patients at risk of grampositive bacteraemia and the impact of empirical administration of vancomycin. Eur J Cancer 32A:1332-1339
20. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trial Group (1991) Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 163:951-958
21. Karp JE, Dick JD, Angelopulos C, Charache P, Green L, Burke PJ, Saral R (1986) Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med 81:237-242
22. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA (1988) Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 108:30-35
23. Einsele H, Hebart H, Löffler H, Rothenhöfer I, Quabeck K, Schäfer U, Schumacher U, Kanz L (1996) PCR monitoring of sequential BAL samples to identify patients at high risk to develop invasive pulmonary aspergillosis post-BMT. Blood 88 [Suppl 1]:abstr 1691
24. Silling-Engelhardt G, Fegeler W, Roos N, Schwarz C, Essink M, Hiddemann W, Büchner T (1994) Interventional treatment of unexplained fever (FUO) and documented infections in neutropenic patients with hematological malignancies: fluconazole versus ampho B/5-FC. Onkologie 17 [Suppl 2]:142
25. Benezra D, Kiehn TE, Gold JWM, Brown AE, Turnbull ADM, Armstrong D (1989) Prospective study of infections in indwelling central venous catheters using quantitative blood cultures. Am J Med 85:495-498
26. de Cicco M, Chiaradia V, Veronesi A, Santini G, Panarello G, Fracasso A, Testa V, Tesio F (1989) Source and route of microbial colonisation of parenteral nutrition catheters. Lancet 2:1258-1261
27. Lecciones JA, Lee JW, Navarro EE, Witebsky FG, Marshall D, Steinberg SM, Pizzo PA, Walsh TJ (1992) Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 14:875-883
28. Behre G, Schedel I, Nentwig B, Wörmann B, Essink M, Hiddemann W (1992) Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins. Antimicrob Agents Chemother 36:2139-2146
29. Schedel I, Dreikhausen U, Nentwig B, Hockenschnieder M, Rauthmann D, Balikcioglu S, Coldewey R, Deicher H (1991) Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med 19:1104-1113
30. Glauser MP (1983) Immunoprophylaxis of gram-negative infections: background for a prophylactic study of purified anticore-glycolipid immunoglobulins in neutropenic patients. Schweiz Med Wochenschr 113 [Suppl 14]:35-39
31. Biesma B, de Vries EGE, Willemse PHB, Sluiter WJ, Portmus PE, Limburg PC, Stern AC, Vellenga E (1990) Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. Eur J Cancer 26:932-936
32. Vellenga E, Uyl-de Groot CA, de Wit R, Keizer HJ, Löwenberg B, ten Haaft MA, de Witte TJM, Verhagen CAH, Stoter GJ, Rutten FFH, Mulder NH, Smid WM, de Vries EGE (1996) Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol 14:619-627
33. Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, Sheridan WP, Kefford RF, Cebon J, Olver I, McKendrick J, Toner G, Bradstock K, Lieschke M, Cruickshank S, Tomita DK, Hoffman EW, Fox RM, Morstyn G (1994) Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 121:492-501
34. Mayordomo JI, Rivera F, Díaz-Puente MT, Lianes P, Colomer R, López-Brea M, López E, Paz-Ares L, Hitt R, Garcia-Ribas I, Cubedo R, Alonso S, Cortès-Funes H (1995) Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 87:803-808
35. Riikonen P, Saarinen UM, Mäkipernaa A, Hovi L, Komulainen A, Pihkala J, Jalanko H (1994) Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double-blind placebo-controlled study in children. Pediatr Infect Dis J 13:197-202
36. Clift RA, Buckner CD (1984) Granulocyte transfusions. Am J Med 76:631-636
37. E.O.R.T.C. International Antimicrobial Therapy Project Group (1983) Early granulocyte transfusions in high-risk febrile neutropenic patients. Schweiz Med Wochenschr 113 [Suppl 14]:46-48
38. Winston DJ, Ho WG, Gale RP (1982) Therapeutic granulocyte transfusions for documented infections. A controlled trial in ninety-five infectious granulocytopenic episodes. Ann Intern Med 97:509-515
39. Bhatia S, McCullough J, Perry EH, Clay M, Ramsay NK, Neglia JP (1994) Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marow transplantation. Transfusion 34:226-232
40. Fleming R, Anaissie E, O'Brien S, Kantarjian H, Estey E, Lichtiger B, Jendiroba D, Freireich E (1996) Treatment of neutropenia related fungal infections with G-CSF-mobilized granulocyte transfusions. Blood 88 [Suppl 1]:331a
41. Taylor K, Moore D, Kelly C, Wright S, Rodwell R, Bashford J, Marlton P, Bunce I, Rentoul A, Williams N, Price N, Morton AJ, Passuello F, Renwick J, Lape K, Thompson J (1996) Safety and logistical use of filgrastim-mobilised granulocytes in early management of severe neutropenic sepsis in acute leukemia/autograft. Blood 88 [Suppl 1]:349a